What's the most recent regulatory action in Primary cutaneous T-cell lymphoma?

Most recent: Topicort — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/primary-cutaneous-t-cell-lymphoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Primary cutaneous T-cell lymphoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Primary cutaneous T-cell lymphoma (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Primary cutaneous T-cell lymphoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Poteligeo	MOGAMULIZUMAB	Kyowa Kirin	Chemokine Receptor Type 4 Interaction [EPC]	C-C chemokine receptor type 4	2018-01-01
Farydak	PANOBINOSTAT	Secura	Histone Deacetylase Inhibitor	Histone deacetylase 4	2015-01-01
Istodax	ROMIDEPSIN	Teva Pharms Usa Inc	Histone Deacetylase Inhibitor	HDACs	2009-01-01
Zolinza	VORINOSTAT	Merck & Co.	Histone Deacetylase Inhibitor [EPC]	Histone deacetylase 6	2006-01-01
Ontak	E7777	Eisai	CD25-directed Cytotoxin	Interleukin-2 receptor	1999-01-01
Targretin	BEXAROTENE	Bausch Health	Retinoid [EPC]	Retinoic acid receptor RXR-beta	1999-01-01
Ontak	DENILEUKIN DIFTITOX	Eisai	CD25-directed Cytotoxin [EPC]	Interleukin-2 receptor	1999-01-01
Flonase	fluticasone propionate	GSK (GlaxoSmithKline)	Inhaled/intranasal corticosteroid	Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor	1994-11-04
Dermatop	PREDNICARBATE	Bausch Health	Corticosteroid	Glucocorticoid receptor	1991-01-01
Ultravate	ulobetasol propionate	Ranbaxy	ulobetasol propionate	Glucocorticoid receptor	1990-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-16 — Topicort · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 8 drugs in Primary cutaneous T-cell lymphoma
Bausch Health · 3 drugs in Primary cutaneous T-cell lymphoma
Merck & Co. · 3 drugs in Primary cutaneous T-cell lymphoma
Eisai · 2 drugs in Primary cutaneous T-cell lymphoma
Generic (originally Schering) · 2 drugs in Primary cutaneous T-cell lymphoma
Creighton University · 1 drug in Primary cutaneous T-cell lymphoma
Astellas Pharma · 1 drug in Primary cutaneous T-cell lymphoma
GSK (GlaxoSmithKline) · 1 drug in Primary cutaneous T-cell lymphoma
Fougera Pharms Inc · 1 drug in Primary cutaneous T-cell lymphoma
Generic (originally Merck) · 1 drug in Primary cutaneous T-cell lymphoma
Generic (originally Merck/Upjohn) · 1 drug in Primary cutaneous T-cell lymphoma
Eurofarma · 1 drug in Primary cutaneous T-cell lymphoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Primary cutaneous T-cell lymphoma:

Cite this brief

Drug Landscape (2026). Primary cutaneous T-cell lymphoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/primary-cutaneous-t-cell-lymphoma. Accessed 2026-06-10.

Primary cutaneous T-cell lymphoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing